The 26S proteasome is a multifaceted target for anti-cancer therapies

Oncotarget

Volumn 6, Issue 28, 2015, Pages 24733-24749

  Grigoreva, Tatyana A ^a   Tribulovich, Vyacheslav G ^a   Garabadzhiu, Alexander V ^a   Melino, Gerry ^a,b   Barlev, Nickolai A ^c  

^a ST PETERSBURG STATE INSTITUTE OF TECHNOLOGY TECHNICAL UNIVERSITY   (Russian Federation)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c INSTITUTE OF CYTOLOGY   (Russian Federation)

Author keywords

Combined anti cancer therapy; Proteasome; Proteasome inhibitors; Ubiquitin dependent proteolysis

Indexed keywords

AM114; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARFILZOMIB; CELASTROL; CURCUMIN; CYSTEINE PROTEINASE; DELANZOMIB; DISULFIRAM; EPIGALLOCATECHIN GALLATE; EPOXOMICIN; FELUTAMIDE B; GLIDOBACTIN A; HYDROXYUREA; IXAZOMIB; LACTACYSTIN BETA LACTONE; NC 001; NC 022; OPROZOMIB; PI 083; PRISTIMERIN; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SYRINGOLIN A; TCH 013; TP 110; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YU 102; ANTINEOPLASTIC AGENT; ATP DEPENDENT 26S PROTEASE;

ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; DEGENERATIVE DISEASE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; LYSOSOME; NEOPLASM; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; STRESS; UBIQUITINATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEOLYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; UBIQUITINATION;

EID: 84944463518     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4619     Document Type: Article

References (138)

1. Brandman O, Stewart-Ornstein J, Wong D, Larson A, Williams CC, Li GW, Zhou S, King D, Shen PS, Weibezahn J, Dunn JG, Rouskin S, Inada T, Frost A, Weissman JS. A ribosome-bound quality control complex triggers degradation of nascent peptides and signals translation stress. Cell. 2012; 151:1042-1054.
2. Defenouillere Q, Yao Y, Mouaikel J, Namane A, Galopier A, Decourty L, Doyen A, Malabat C, Saveanu C, Jacquier A, Fromont-Racine M. Cdc48-associated complex bound to 60S particles is required for the clearance of aberrant translation products. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:5046-5051.
3. Verma R, Oania RS, Kolawa NJ, Deshaies RJ. Cdc48/p97 promotes degradation of aberrant nascent polypeptides bound to the ribosome. eLife. 2013; 2:e00308.
4. Delcros JG, Floc'h MB, Prigent C, Arlot-Bonnemains Y. Proteasome inhibitors as therapeutic agents: current and future strategies. Current medicinal chemistry. 2003; 10:479-503.
5. Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2014; Dec :pii. S0140-673660493-1.
6. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chemistry & biology. 2012; 19:99-115.
7. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomibinduced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008; 112:1593-1599.
8. Knight RA, Gostev M, Ilisavskii S, Willis AE, Melino G, Antonov AV. Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays. Oncotarget. 2014; 5:659-666.
9. Amelio I, Gostev M, Knight RA, Willis AE, Melino G, Antonov AV. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell death & disease. 2014; 5:e1051.
10. Antonov AV, Krestyaninova M, Knight RA, Rodchenkov I, Melino G, Barlev NA. PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome. Oncogene. 2014; 33:1621-1628.
11. Sorokin AV, Kim ER, Ovchinnikov LP. Proteasome system of protein degradation and processing. Biochemistry Biokhimiia. 2009; 74:1411-1442.
12. Adams J. The proteasome: a suitable antineoplastic target. Nature reviews Cancer. 2004; 4:349-360.
13. Mittenberg AG, Moiseeva TN, Barlev NA. Role of proteasomes in transcription and their regulation by covalent modifications. Front Biosci. 2008; 13:7184-92.
14. Konstantinova IM, Tsimokha AS, Mittenberg AG. Role of proteasomes in cellular regulation. International review of cell and molecular biology. 2008; 267:59-124.
15. Kulichkova VA, Tsimokha AS, Fedorova OA, Moiseeva TN, Bottril A, Lezina L, Gauze LN, Konstantinova IM, Mittenberg AG, Barlev NA. 26S proteasome exhibits endoribonuclease activity controlled by extra-cellular stimuli. Cell cycle. 2010; 9:840-849.
16. Fedorova OA, Moiseeva TN, Nikiforov AA, Tsimokha AS, Livinskaya VA, Hodson M, Bottrill A, Evteeva IN, Ermolayeva JB, Kuznetzova IM, Turoverov KK, Eperon I, Barlev NA. Proteomic analysis of the 20S proteasome (PSMA3)-interacting proteins reveals a functional link between the proteasome and mRNA metabolism. Biochemical and biophysical research communications. 2011; 416:258-265.
17. Tsimokha AS, Kulichkova VA, Karpova EV, Zaykova JJ, Aksenov ND, Vasilishina AA, Kropotov AV, Antonov A, Barlev NA. DNA damage modulates interactions between microRNAs and the 26S proteasome. Oncotarget. 2014; 5:3555-3567.
18. Bhattacharyya S, Yu H, Mim C, Matouschek A. Regulated protein turnover: snapshots of the proteasome in action. Nature reviews Molecular cell biology. 2014; 15:122-133.
19. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological reviews. 2002; 82:373-428.
20. Petit F, Jarrousse AS, Dahlmann B, Sobek A, Hendil KB, Buri J, Briand Y, Schmid HP. Involvement of proteasomal subunits zeta and iota in RNA degradation. The Biochemical journal. 1997; 326:93-98.
21. Moiseeva TN, Bottrill A, Melino G, Barlev NA. DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity. Oncotarget. 2013; 4:1338-1348.
22. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annual review of biochemistry. 1999; 68:1015-1068.
23. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. The active sites of the eukaryotic 20S proteasome and their involvement in subunit precursor processing. The Journal of biological chemistry. 1997; 272:25200-25209.
24. Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, Ploegh HL, Thornberry NA, Goldberg AL. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. The Journal of biological chemistry. 2003; 278:35869-35877.
25. Groll M, Heinemeyer W, Jager S, Jäger S, Ullrich T, Bochtler M, Wolf DH, Huber R. The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:10975-10983.
26. Orlowski M, Cardozo C, Michaud C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry. 1993; 32:1563-1572.
27. Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des. 2013; 19:4140-4151.
28. Pickering AM, Davies KJ. Differential roles of proteasome and immunoproteasome regulators Pa28alphabeta, Pa28gamma and Pa200 in the degradation of oxidized proteins. Archives of biochemistry and biophysics. 2012; 523:181-190.
29. Glickman MH, Rubin DM, Coux O, Wefes I, Pfeifer G, Cjeka Z, Baumeister W, Fried VA, Finley D. A subcomplex of the proteasome regulatory particle required for ubiquitinconjugate degradation and related to the COP9-signalosome and eIF3. Cell. 1998; 94:615-623.
30. D'Arcy P, Linder S. Proteasome deubiquitinases as novel targets for cancer therapy. The international journal of biochemistry & cell biology. 2012; 44:1729-1738.
31. Forster A, Masters EI, Whitby FG, Robinson H, Hill CP. The 1.9 Å structure of a proteasome-11S activator complex and implications for proteasome-PAN/PA700 interactions. Molecular cell biology. 2005; 18:589-599.
32. Schwechheimer C. The COP9 signalosome (CSN): an evolutionary conserved proteolysis regulator in eukaryotic development. Biochimica et biophysica acta. 2004; 1695:45-54.
33. Barthelme D, Sauer RT. Identification of the Cdc48*20S proteasome as an ancient AAA+ proteolytic machine. Science. 2012; 337:843-846.
34. Kumar B, Kim YC, DeMartino GN. The C terminus of Rpt3, an ATPase subunit of PA700 (19 S) regulatory complex, is essential for 26 S proteasome assembly but not for activation. The Journal of biological chemistry. 2010; 285:39523-39535.
35. Pick E, Berman TS. Formation of alternative proteasomes: same lady, different cap?. FEBS letters. 2013; 587:389-393.
36. Stadtmueller BM, Hill CP. Proteasome activators. Molecular cell. 2011; 41:8-19.
37. Ramadan K. p97/VCP-and Lys48-linked polyubiquitination form a new signaling pathway in DNA damage response. Cell cycle. 2012; 11:1062-1069.
38. Forouzan D, Ammelburg M, Hobel CF, Stroh LJ, Sessler N, Martin J, Lupas AN. The archaeal proteasome is regulated by a network of AAA ATPases. The Journal of biological chemistry. 2012; 287:39254-39262.
39. Savulescu AF, Glickman MH. Proteasome activator 200: the heat is on Molecular & Cellular Proteomics. 2011;R110.006890.
40. Hirano Y, Hayashi H, Iemura S, Hendil KB, Niwa S, Kishimoto T, Kasahara M, Natsume T, Tanaka K, Murata S. Cooperation of multiple chaperones required for the assembly of mammalian 20S proteasomes. Molecular cell. 2006; 24:977-984.
41. Le Tallec B, Barrault MB, Courbeyrette R, Guerois R, Marsolier-Kergoat MC, Peyroche A. 20S proteasome assembly is orchestrated by two distinct pairs of chaperones in yeast and in mammals. Molecular cell. 2007; 27:660-674.
42. Chen Q, Thorpe J, Dohmen JR, Li F, Keller JN. Ump1 extends yeast lifespan and enhances viability during oxidative stress: central role for the proteasome?. Free radical biology & medicine. 2006; 40:120-126.
43. Tomko RJ Jr, Hochstrasser M. Molecular architecture and assembly of the eukaryotic proteasome. Annual review of biochemistry. 2013; 82:415-445.
44. Lehmann A, Niewienda A, Jechow K, Janek K, Enenkel C. Ecm29 fulfils quality control functions in proteasome assembly. Molecular cell. 2010; 38:879-888.
45. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008; 112:2489-2499.
46. Izumikawa M, Hashimoto J, Hirokawa T, Sugimoto S, Kato T, Takagi M, Shin-Ya K. JBIR-22, an inhibitor for proteinprotein interaction of the homodimer of proteasome assembly factor 3. Journal of natural products. 2010; 73:628-631.
47. Yao T, Song L, Jin J, Cai Y, Takahashi H, Swanson SK, Washburn MP, Florens L, Conaway RC, Cohen RE, Conaway JW. Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in the Ino80 chromatin-remodeling complex. Molecular cell. 2008; 31:909-917.
48. Butler LR, Densham RM, Jia J, Garvin AJ, Stone HR, Shah V, Weekes D, Festy F, Beesley J, Morris JR. The proteasomal de-ubiquitinating enzyme POH1 promotes the double-strand DNA break response. The EMBO journal. 2012; 31:3918-3934.
49. Tirat A, Schilb A, Riou V, Leder L, Gerhartz B, Zimmermann J, Worpenberg S, Eidhoff U, Freuler F, Stettler T, Mayr L, Ottl J, Leuenberger B, Filipuzzi I. Synthesis and characterization of fluorescent ubiquitin derivatives as highly sensitive substrates for the deubiquitinating enzymes UCH-L3 and USP-2. Analytical biochemistry. 2005; 343:244-255.
50. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005; 123:773-786.
51. Reyes-Turcu FE, Horton JR, Mullally JE, Heroux A, Cheng X, Wilkinson KD. The ubiquitin binding domain ZnF UBP recognizes the C-terminal diglycine motif of unanchored ubiquitin. Cell. 2006; 124:1197-1208.
52. Yao T, Cohen RE. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature. 2002; 419:403-407.
53. Koulich E, Li X, DeMartino GN. Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. Molecular biology of the cell. 2008; 19:1072-1082.
54. Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:192-197.
55. Brnjic S, D'arcy P, Larsson R, Linder S. Method For The Inhibition Of Deubiquitinating Activity. U.S. Patent 2013/0079370March 2013; .
56. D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nature Medicine. 2011; 17:1636-1640.
57. Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014; 123:706-716.
58. Liu N, Liu C, Li X, Liao S, Song W, Yang C, Zhao C, Huang H, Guan L, Zhang P, Liu S, Hua X, Chen X, et al. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Scientific Reports. 2014; 4:5240.
59. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC, Gartner C, Dimova N, Hanna J, Gygi SP, Wilson SM, King RW, Finley D. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010; 467:179-184.
60. Haglund C, Mohanty C, Fryknäs M, D'Arcy P, Larsson R, Linder S, Rickardson L. MedChemComm. 2014; 5:376-385.
61. Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RB. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell. 2013; 24:791-805.
62. Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ, Patricelli MP, Hodder P, Rosen H, Deshaies RJ. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:4834-4839.
63. Chou TF, Li K, Frankowski KJ, Schoenen FJ, Deshaies RJ. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem. 2013; 8:297-312.
64. Smoum R, Rubinstein A, Dembitsky VM, Srebnik M. Boron containing compounds as protease inhibitors. Chemical reviews. 2012; 112:4156-4220.
65. Hines J, Groll M, Fahnestock M, Crews CM. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chemistry & biology. 2008; 15:501-512.
66. Momose I, Umezawa Y, Hirosawa S, Iijima M, Iinuma H, Ikeda D. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome. Bioscience, biotechnology, and biochemistry. 2005; 69:1733-1742.
67. Momose I, Sekizawa R, Iinuma H, Takeuchi T. Inhibition of proteasome activity by tyropeptin A in PC12 cells. Bioscience, biotechnology, and biochemistry. 2002; 66:2256-2258.
68. Clerc J, Li N, Krahn D, Groll M, Bachmann AS, Florea BI, Overkleeft HS, Kaiser M. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity. Chemical communications. 2011; 47:385-387.
69. Geurink PP, van der Linden WA, Mirabella AC, Gallastegui N, de Bruin G, Blom AE, Voges MJ, Mock ED, Florea BI, van der Marel GA, Driessen C, van der Stelt M, Groll M, et al. Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. Journal of medicinal chemistry. 2013; 56:1262-1275.
70. Britton M, Lucas MM, Downey SL, Screen M, Pletnev AA, Verdoes M, Tokhunts RA, Amir O, Goddard AL, Pelphrey PM, Wright DL, Overkleeft HS, Kisselev AF. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chemistry & biology. 2009; 16:1278-1289.
71. Myung J, Kim KB, Lindsten K, Dantuma NP, Crews CM. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Molecular cell. 2001; 7:411-420.
72. Baldisserotto A, Destro F, Vertuani G, Marastoni M, Gavioli R, Tomatis R. N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors. Bioorganic & medicinal chemistry. 2009; 17:5535-5540.
73. Groll M, Nazif T, Huber R, Bogyo M. Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome. Chemistry & biology. 2002; 9:655-662.
74. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. Journal of Biological Chemistry. 2001; 276:13322-13330.
75. Smith DM, Wang Z, Kazi A, Li LH, Chan TH, Dou QP. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Molecular medicine. 2002; 8:382-392.
76. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer research. 2008; 68:7283-7292.
77. Santoro AM, Lo Giudice MC, D'Urso A, Lauceri R, Purrello R, Milardi D. Cationic Porphyrins Are Reversible Proteasome Inhibitors. Journal of the American Chemical Society. 2012; 134:10451-10457.
78. Hasegawa M, Kinoshita K, Nishimura C, Matsumura U, Shionyu M, Ikeda S, Mizukami T. Affinity labeling of the proteasome by a belactosin A derived inhibitor. Bioorganic & medicinal chemistry letters. 2008; 18:5668-5671.
79. Ge Y, Kazi A, Marsilio F, Luo Y, Jain S, Brooks W, Daniel KG, Guida WC, Sebti SM, Lawrence HR. Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. Journal of medicinal chemistry. 2012; 55:1978-1998.
80. Mi L, Gan N, Chung FL. Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells. Carcinogenesis. 2011; 32:216-223.
81. Tiedemann RE, Schmidt J, Keats JJ, Shi CX, Zhu YX, Palmer SE, Mao X, Schimmer AD, Stewart AK. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood. 2009; 113:4027-4037.
82. Walcott SE, Heikkila JJ. Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis A6 cells. Comparative biochemistry and physiology Part A, Molecular & integrative physiology. 2010; 156:285-293.
83. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer research. 2006; 66:4758-4765.
84. Achanta G, Modzelewska A, Feng L, Khan SR, Huang P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Molecular pharmacology. 2006; 70:426-433.
85. Lansdell TA, Hurchla MA, Xiang J, Hovde S, Weilbaecher KN, Henry RW, Tepe JJ. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo. ACS chemical biology. 2013; 8:578-587.
86. Gallastegui N, Beck P, Arciniega M, Huber R, Hillebrand S, Groll M. Hydroxyureas as noncovalent proteasome inhibitors. Angewandte Chemie. 2012; 51:247-249.
87. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer research. 2006; 66:10425-10433.
88. Li L, Yang H, Chen D, Cui C, Dou QP. Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells. Toxicology and applied pharmacology. 2008; 229:206-214.
89. Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S, Yan B, Reddy GP, Dou QP. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer research. 2007; 67:1636-1644.
90. Jackson G, Einsele H, Moreau P, Miguel JS. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer treatment reviews. 2005; 31:591-602.
91. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer research. 2004; 64:5036-5043.
92. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006; 14:451-456.
93. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008; 111:2765-2775.
94. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer research. 2007; 67:6383-6391.
95. Orlowski RZ. In: Advances in Biology and Therapy of Multiple Myeloma; Munshi NC, Anderson KC, Eds. New York: Springer 2013; Vol.1, pp: 157-80.
96. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). Journal of medicinal chemistry. 2009; 52:3028-3038.
97. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomibinduced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008; 112:1593-1599.
98. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Current cancer drug targets. 2011; 11:254-284.
99. Dick LR, Fleming PE. Building on bortezomib: secondgeneration proteasome inhibitors as anti-cancer therapy. Drug discovery today. 2010; 15:243-249.
100. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer research. 2010; 70:1970-1980.
101. Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013; 27:430-440.
102. Joazeiro CA, Anderson KC, Hunter T. Proteasome inhibitor drugs on the rise. Cancer research. 2006; 66:7840-7842.
103. Groll M, Huber R, Potts BC. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. Journal of the American Chemical Society. 2006; 128:5136-5141.
104. Nett M, Gulder TA, Kale AJ, Hughes CC, Moore BS. Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica. Journal of medicinal chemistry. 2009; 52:6163-6167.
105. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angewandte Chemie. 2003; 42:355-357.
106. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O. The potential of proteasome inhibitors in cancer therapy. Expert opinion on investigational drugs. 2008; 17:879-895.
107. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer cell. 2005; 8:407-419.
108. Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014; 124:1038-1046.
109. Kisselev AF, Groettrup M. Subunit specific inhibitors of proteasomes and their potential for immunomodulation. Current opinion in chemical biology. 2014; 23:16-22.
110. Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasomespecific inhibitors (IPSIs). Current cancer drug targets. 2011; 11:285-295.
111. Dou QP. Targeting tumor ubiquitin-proteasome pathway with new and old drugs. Current cancer drug targets. 2011; 11:236-238.
112. Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S, Hunter K, Ruggeri B, Berenson JR. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leukemia research. 2012; 36:1422-1427.
113. Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. The Journal of urology. 2007; 178:2378-2383. discussion 2383-2374.
114. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R, Garcia-Larana J, Bengoechea E, Martin A, Mediavilla JD, Palomera L, de Arriba F, Gonzalez Y, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. The lancet oncology. 2010; 11:934-941.
115. Mato AR, Feldman T, Goy A. Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. The oncologist. 2012; 17:694-707.
116. Jagadeesh D, Smith MR. Novel targeted therapies in peripheral T cell lymphoma. Discovery medicine. 2013; 15:367-378.
117. Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosee P, Kirchner H, Kiewe P, et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Annals of hematology. 2012; 91:1765-1772.
118. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nature medicine. 2011; 17:330-339.
119. Chen YC, Huang WJ, Hsu JL, Yu CC, Wang WT, Guh JH. A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers-the role of histone deacetylase and endoplasmic reticulum stress. The Prostate. 2013; 73:1270-1280.
120. Jones DR, Moskaluk CA, Gillenwater HH, Petroni GR, Burks SG, Philips J, Rehm PK, Olazagasti J, Kozower BD, Bao Y. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2012; 7:1683-1690.
121. Abaza MS, Bahman AM, Al-Attiyah RJ, Kollamparambil AM. Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012; 33:1951-1972.
122. Huang H, Liu N, Yang C, Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, et al. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. PloS one. 2012; 7:e52576.
123. Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M, Anderson KC. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. British journal of haematology. 2011; 153:729-740.
124. Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:2792-2802.
125. Ishii T, Seike T, Nakashima T, Juliger S, Maharaj L, Soga S, Akinaga S, Cavenagh J, Joel S, Shiotsu Y. Antitumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood cancer journal. 2012; 2:e68.
126. Heimberger T, Andrulis M, Riedel S, Stuhmer T, Schraud H, Beilhack A, Bumm T, Bogen B, Einsele H, Bargou RC, Chatterjee M. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. British journal of haematology. 2013; 160:465-476.
127. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nature reviews Drug discovery. 2014; 13:140-156.
128. De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer chemotherapy and pharmacology. 2013; 71:867-881.
129. Zanotto-Filho A, Braganhol E, Battastini AM, Moreira JC. Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling. Investigational new drugs. 2012; 30:2252-2262.
130. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer research. 2008; 68:6698-6707.
131. Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, et al. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. International journal of cancer Journal international du cancer. 2012; 130:967-978.
132. Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W, 3rd, Hollander MC, Dennis PA. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell death & disease. 2012; 3:e353.
133. Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer chemotherapy and pharmacology. 2013; 71:1567-1576.
134. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. European journal of pharmacology. 2009; 625:234-246.
135. Auner HW, Moody AM, Ward TH, Kraus M, Milan E, May P, Chaidos A, Driessen C, Cenci S, Dazzi F, Rahemtulla A, Apperley JF, Karadimitris A, Dillon N. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PloS one. 2013; 8:e74415.
136. Moriya S, Che XF, Komatsu S, Abe A, Kawaguchi T, Gotoh A, Inazu M, Tomoda A, Miyazawa K. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. International journal of oncology. 2013; 42:1541-1550.
137. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Current cancer drug targets. 2011; 11:239-253.
138. Goktas S, Baran Y, Ural AU, Yazici S, Aydur E, Basal S, Avcu F, Pekel A, Dirican B, Beyzadeoglu M. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology. 2010; 75:793-798.